BioCryst reported total net revenue of $180.3 million and operating profit of $53.3 million. The company also received FDA approval for the 150 mg pellet formulation of ORLADEYO and raised full-year revenue guidance to $715 million to $730 million.
BioCryst reported total net revenue of $180.3 million and operating profit of $53.3 million. The company also received FDA approval for the 150 mg pellet formulation of ORLADEYO and raised full-year revenue guidance to $715 million to $730 million.